By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MicroRNA-based technology startup Firefly BioWorks has raised about $2 million in a private financing, which it plans to use to test its platform directed at cancer-related research.

Firefly co-founder and CEO Davide Marini, told GenomeWeb Daily News that the company plans to test the product with a select group of researchers to assess its utility but declined to provide further details. He also declined to identify investors in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.